-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Wedbush Comments on TCR2 Therapeutics Inc.'s Q3 2022 Earnings (NASDAQ:TCRR)
Wedbush Comments on TCR2 Therapeutics Inc.'s Q3 2022 Earnings (NASDAQ:TCRR)
TCR2 Therapeutics Inc. (NASDAQ:TCRR – Get Rating) – Stock analysts at Wedbush cut their Q3 2022 earnings estimates for shares of TCR2 Therapeutics in a research note issued to investors on Wednesday, September 28th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.36). The consensus estimate for TCR2 Therapeutics' current full-year earnings is ($3.19) per share. Wedbush also issued estimates for TCR2 Therapeutics' Q4 2022 earnings at ($0.37) EPS and FY2022 earnings at ($2.76) EPS.
Get TCR2 Therapeutics alerts:Several other research analysts have also commented on TCRR. Roth Capital restated a "buy" rating on shares of TCR2 Therapeutics in a report on Monday, August 8th. Truist Financial cut their price target on shares of TCR2 Therapeutics to $18.00 in a report on Tuesday, August 23rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.71.
TCR2 Therapeutics Trading Up 4.7 %
NASDAQ:TCRR opened at $1.80 on Monday. The firm has a market cap of $69.49 million, a price-to-earnings ratio of -0.60 and a beta of 1.79. TCR2 Therapeutics has a 12-month low of $1.60 and a 12-month high of $8.82. The company's 50-day moving average is $2.78 and its two-hundred day moving average is $2.69.TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.05).
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in TCR2 Therapeutics by 113.2% during the 1st quarter. GSA Capital Partners LLP now owns 158,593 shares of the company's stock valued at $438,000 after acquiring an additional 84,191 shares in the last quarter. Marquette Asset Management LLC increased its position in TCR2 Therapeutics by 20.7% in the 2nd quarter. Marquette Asset Management LLC now owns 40,163 shares of the company's stock worth $116,000 after buying an additional 6,901 shares during the period. Jane Street Group LLC bought a new position in TCR2 Therapeutics in the 2nd quarter worth approximately $38,000. Orion Portfolio Solutions LLC bought a new stake in shares of TCR2 Therapeutics during the second quarter valued at approximately $39,000. Finally, Acadian Asset Management LLC increased its position in shares of TCR2 Therapeutics by 3,250.7% during the first quarter. Acadian Asset Management LLC now owns 479,518 shares of the company's stock valued at $1,322,000 after purchasing an additional 465,207 shares during the period. 64.56% of the stock is owned by institutional investors and hedge funds.
About TCR2 Therapeutics
(Get Rating)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
Further Reading
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
TCR2 Therapeutics Inc. (NASDAQ:TCRR – Get Rating) – Stock analysts at Wedbush cut their Q3 2022 earnings estimates for shares of TCR2 Therapeutics in a research note issued to investors on Wednesday, September 28th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.36). The consensus estimate for TCR2 Therapeutics' current full-year earnings is ($3.19) per share. Wedbush also issued estimates for TCR2 Therapeutics' Q4 2022 earnings at ($0.37) EPS and FY2022 earnings at ($2.76) EPS.
TCR2治療公司(納斯達克:TCRR-GET評級)--韋德布什的股票分析師在9月28日星期三發給投資者的一份研究報告中下調了他們對TCR2治療公司股票2022年第三季度的收益預期。韋德布什分析師D.尼倫加滕現在預計,該公司本季度每股收益將為0.82美元,低於此前預測的0.36美元。對TCR2治療公司目前全年收益的普遍估計為每股3.19美元。韋德布什還發布了對TCR2治療公司2022年第四季度每股收益(0.37美元)和2022財年每股收益(2.76美元)的估計。
Several other research analysts have also commented on TCRR. Roth Capital restated a "buy" rating on shares of TCR2 Therapeutics in a report on Monday, August 8th. Truist Financial cut their price target on shares of TCR2 Therapeutics to $18.00 in a report on Tuesday, August 23rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.71.
其他幾位研究分析師也對TCRR發表了評論。Roth Capital在8月8日星期一的一份報告中重申了對TCR2治療公司股票的“買入”評級。Truist Financial在8月23日星期二的一份報告中將TCR2治療公司的股票目標價下調至18.00美元。兩名研究分析師對該股的評級為持有,四名分析師對該股的評級為買入。根據MarketBeat的數據,該股目前的平均評級為“適度買入”,共識目標價為16.71美元。
TCR2 Therapeutics Trading Up 4.7 %
TCR2治療公司股價上漲4.7%
TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.05).
TCR2治療公司(納斯達克代碼:TCRR-GET Rating)上一次公佈季度收益是在8月8日星期一。該公司公佈本季度每股收益為0.82美元,低於分析師普遍預期的0.77美元和0.05美元。
Institutional Inflows and Outflows
機構資金流入和流出
Hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in TCR2 Therapeutics by 113.2% during the 1st quarter. GSA Capital Partners LLP now owns 158,593 shares of the company's stock valued at $438,000 after acquiring an additional 84,191 shares in the last quarter. Marquette Asset Management LLC increased its position in TCR2 Therapeutics by 20.7% in the 2nd quarter. Marquette Asset Management LLC now owns 40,163 shares of the company's stock worth $116,000 after buying an additional 6,901 shares during the period. Jane Street Group LLC bought a new position in TCR2 Therapeutics in the 2nd quarter worth approximately $38,000. Orion Portfolio Solutions LLC bought a new stake in shares of TCR2 Therapeutics during the second quarter valued at approximately $39,000. Finally, Acadian Asset Management LLC increased its position in shares of TCR2 Therapeutics by 3,250.7% during the first quarter. Acadian Asset Management LLC now owns 479,518 shares of the company's stock valued at $1,322,000 after purchasing an additional 465,207 shares during the period. 64.56% of the stock is owned by institutional investors and hedge funds.
對衝基金最近買賣了該公司的股票。第一季度,GSA Capital Partners LLP在TCR2治療公司的持股增加了113.2%。GSA Capital Partners LLP在上個季度增持了84,191股後,現在擁有158,593股該公司股票,價值438,000美元。Marquette Asset Management LLC在第二季度將其在TCR2治療公司的頭寸增加了20.7%。Marquette Asset Management LLC在此期間又購買了6901股,現在擁有40,163股該公司股票,價值11.6萬美元。簡街集團在第二季度購買了TCR2治療公司的一個新頭寸,價值約3.8萬美元。Orion Portfolio Solutions LLC在第二季度購買了TCR2治療公司的新股份,價值約3.9萬美元。最後,Acadian Asset Management LLC在第一季度將其在TCR2治療公司的股份增加了3,250.7%。Acadian Asset Management LLC在此期間又購買了465,207股,目前擁有479,518股該公司股票,價值1,322,000美元。64.56%的股票由機構投資者和對衝基金持有。
About TCR2 Therapeutics
關於TCR2治療公司
(Get Rating)
(獲取評級)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
TCR2治療公司是一家臨牀階段免疫治療公司,專注於為癌症患者開發新型T細胞受體(TCR)療法。該公司的主要候選產品包括Gavo-cel,一種針對Mesothelin陽性實體腫瘤的單一TCR融合結構T細胞(TRUC-T細胞),正在進行I/II期臨牀試驗,用於治療非小細胞肺癌(NSCLC)、卵巢癌、惡性胸膜/腹膜間皮瘤和膽管癌。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免費獲取StockNews.com關於TCR2治療的研究報告(TCRR)
- 阿徹·丹尼爾斯·米德蘭:49年增長的紅利英雄
- 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎?
- 麥格納國際是您的汽車和電動汽車一站式庫存
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat:回顧一週9/26-9/30
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《TCR2治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對TCR2治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧